OR WAIT null SECS
March 29, 2021
The agency’s human medicines committee has approved new manufacturing sites for COVID-19 vaccines.
March 25, 2021
EFPIA and Vaccines Europe urge the avoidance of any reactionary measures that could disrupt the production and delivery of COVID-19 vaccines.
AstraZeneca has released the results of its primary analysis of the Phase III trial data evaluating its COVID-19 vaccine.
ABPI has responded to the publication of the UK government’s plans for the future of clinical research.
March 24, 2021
After releasing US Phase III trial data for AZD1222, more questions have been raised with AstraZeneca concerning potentially outdated information that could provide an incomplete view of efficacy.
Is FDA approving too many new drugs and added indications too quickly based on surrogate endpoints that fail to pan out?
The agency says that data do not support the use of ivermectin to prevent or treat COVID-19 outside of clinical trials.
March 23, 2021
FDA has issued warning letters to two US-based manufacturers, Honest Globe and Biolyte Laboratories, for selling products labeled as containing cannabidiol in ways that violate the Federal Food, Drug, and Cosmetic Act.
CPhI’s post-pandemic report predicts strong progression in pharma innovation, with breakthroughs in multi-modal disease therapies, a transformative effect of mRNA platforms, and significant growth in contract services.
March 19, 2021
MHRA and EMA have confirmed that the benefits of the AstraZeneca COVID-19 vaccine continue to outweigh the risk of side effects.